Business Wire

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy

Share

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.

Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.

“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”

FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.

“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”

About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.

About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.

About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Biocytogen
Platform and Assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEEE Announces Decision on Its Standards-related Patent Policy30.9.2022 18:31:00 CEST | Press release

The IEEE Standards Association Board of Governors (IEEE SA BOG) took action to update the Patent Policy for IEEE standards development, which will go into effect 01 January 2023. These updates are intended to improve the clarity of IEEE’s standards processes related to patented technologies, while offering more options for stakeholders. In accordance with IEEE SA’s policies and procedures, the following resolutions were approved by consensus without objections by the full IEEE SA BOG. The IEEE SA BOG approved proposed updates to the IEEE SA Standards Board Bylaws, effective 01 January 2023. The IEEE SA BOG approved proposed updates to the IEEE SA Letter of Assurance (LOA) form, effective 01 January 2023. The IEEE SA BOG approved proposed updates to the patent policy FAQs, effective 01 January 2023. For the same IEEE standard, in instances where there is one Submitter of an Accepted LOA under the 2015 policy and another Submitter of an Accepted LOA under a subsequent policy or using the

Calling All Sake Aficionados! October 1st Is "Sake Day." Let's Kampai Together!! (Kampai Means "Toast" in Japanese)30.9.2022 16:00:00 CEST | Press release

There are countless events around the world celebrating the delights of wine and beer; October 1st is known as "Sake Day," where sake lovers worldwide gather, enjoy, and appreciate this delicious beverage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005349/en/ toast (Photo: Business Wire) Sake Day was set as October 1st by the Japan Sake and Shochu Makers Association (JSS), the largest sake industry organization in Japan with members consisting of some 1,700 producers of sake, Honkaku Shochu, Awamori, and Hon-Mirin. This date was selected because October 1st marked the beginning of the new brewing season using freshly harvested rice crops. Events celebrating sake have been planned worldwide for Sake Day on October 1st. In Japan, the "Kampai! with Sake Week" event will run for ten days around Sake Day on October 1st, where JSS, prefectural sake organizations, breweries, restaurants, liquor stores, and sake lovers wil

Alkegen Launching Trio of New High Efficiency Filtration Products for Air, Liquid and Molecular Applications30.9.2022 14:30:00 CEST | Press release

Alkegen, a leading specialty materials platform that provides high performance materials used in advanced applications, announced they will be launching three new High Efficiency Filtration (HEF) products during their exhibition at the upcoming World Filtration Congress in San Diego, CA. These are the first new filtration products launched under the Alkegen brand name since the merger of Lydall and Unifrax last October. “This trio of HEF media – one for air, one for liquid, one for molecular applications – represents the first wave of advanced materials developed and released under our new Alkegen filtration product development team. These launches combine Lydall’s well-known filtration and manufacturing expertise with Unifrax’s proven, rapid innovation capabilities,” said Paul Vallis, President of the Filtration & Catalysis Group. “This is the first of many innovations we expect to deliver as our portfolio evolves to meet the continuous demand for ever-higher efficiency and reduced en

Nexign’s Article Included in TM Forum’s Benchmark Report30.9.2022 13:12:00 CEST | Press release

Nexign, a leading provider of BSS and digitalization solutions, announces that its article has been included in TM Forum’s benchmark report “Telco Revenue Growth: Taking It to the Next Level”. The report investigates the primary sectors and services affecting communications service providers (CSPs) and the areas of growth and decline. It draws on research collected from 33 of the world’s largest operators and serves as a source of valuable information about factors influencing successful telco-to-techco transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005236/en/ Nexign’s Article Included in TM Forum’s Benchmark Report (Photo: Business Wire) Nexign’s article “Harnessing Traditional and New Revenue Streams on Track to Maturity: Harmonization of the BSS Core” discusses key challenges faced by modern CSPs while shifting beyond traditional communications and exploring vertical markets. The authors state that o

The Estée Lauder Companies Launches 2022 Breast Cancer Campaign to Honor 30 th Anniversary and Positively Impact the Global Breast Cancer Community30.9.2022 12:45:00 CEST | Press release

In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/ The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire) Together

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom